NewLink Genetics Corp, a late-stage biopharmaceutical company in Ames, announced it intends to offer up to $50 million of its common stock in an underwritten public offering. The company also plans to grant the underwriters a 30-day option to purchase up to an additional $7.5 million of shares sold in the public offering on the same terms and conditions. NewLink Genetics said it will use the net proceeds from the offering to fund its research and development efforts to further advance its pipeline of product candidates, including the continued clinical development of indoximod, and for working capital and other general corporate purposes.